KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Alnylam Pharmaceuticals (ALNY) Receivables - Other (2018 - 2021)

Alnylam Pharmaceuticals (ALNY) has disclosed Receivables - Other for 3 consecutive years, with $500.0 million as the latest value for Q2 2021.

For Q2 2021, Receivables - Other changed N/A year-over-year to $500.0 million; the TTM value through Jun 2021 reached $500.0 million, changed N/A, while the annual FY2020 figure was $500.0 million, N/A changed from the prior year.
Receivables - Other hit $500.0 million in Q2 2021 for Alnylam Pharmaceuticals, roughly flat from $500.0 million in the prior quarter.
Across five years, Receivables - Other topped out at $500.0 million in Q3 2020 and bottomed at $12.5 million in Q4 2018.
Average Receivables - Other over 3 years is $402.5 million, with a median of $500.0 million recorded in 2020.